Qin Wang, Huai-Gen Zhang, Wei-Rong Yao, Xi-Quan Zhang, Hua-Zhang Tong, Li Liu
{"title":"Postpartum colonic squamous cell carcinoma with a BRAF<sup>V600E</sup> mutation: a case report.","authors":"Qin Wang, Huai-Gen Zhang, Wei-Rong Yao, Xi-Quan Zhang, Hua-Zhang Tong, Li Liu","doi":"10.1186/s13256-025-05491-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Primary squamous cell carcinoma of the colon is a rare malignancy, especially in the postpartum period. Currently, there are no recommended guidelines for this disease. BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer occurs in approximately 8-12% of patients with colorectal cancer.</p><p><strong>Case presentation: </strong>Herein, we report a case of a 37-year-old Chinese woman diagnosed with postpartum descending colon squamous cell carcinoma harboring the BRAF<sup>V600E</sup> mutation, which was treated with radical resection and adjuvant chemotherapy combined with targeted therapy. Eight months later, a new lesion was detected in the colon 40 cm away from the first mass. The patient was enrolled in a clinical trial but withdrew following two treatment cycles because of rapid disease progression. Subsequently, the patient died approximately 6 months after enrolling in the trial.</p><p><strong>Conclusion: </strong>Squamous cell carcinoma of the colon, particularly in postpartum women, is uncommon and often associated with an advanced stage and poor prognosis. Presently, patients with colorectal cancer carrying the BRAF<sup>V600E</sup> mutation typically exhibit a low ratio, an advanced stage, and limited response to existing treatment approaches, resulting in a poor prognosis. Considerable emphasis and effort must be devoted to colonic squamous cell carcinoma, specifically cases harboring the BRAF<sup>V600E</sup> mutation.</p>","PeriodicalId":16236,"journal":{"name":"Journal of Medical Case Reports","volume":"19 1","pages":"410"},"PeriodicalIF":0.8000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362865/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13256-025-05491-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Primary squamous cell carcinoma of the colon is a rare malignancy, especially in the postpartum period. Currently, there are no recommended guidelines for this disease. BRAFV600E-mutated metastatic colorectal cancer occurs in approximately 8-12% of patients with colorectal cancer.
Case presentation: Herein, we report a case of a 37-year-old Chinese woman diagnosed with postpartum descending colon squamous cell carcinoma harboring the BRAFV600E mutation, which was treated with radical resection and adjuvant chemotherapy combined with targeted therapy. Eight months later, a new lesion was detected in the colon 40 cm away from the first mass. The patient was enrolled in a clinical trial but withdrew following two treatment cycles because of rapid disease progression. Subsequently, the patient died approximately 6 months after enrolling in the trial.
Conclusion: Squamous cell carcinoma of the colon, particularly in postpartum women, is uncommon and often associated with an advanced stage and poor prognosis. Presently, patients with colorectal cancer carrying the BRAFV600E mutation typically exhibit a low ratio, an advanced stage, and limited response to existing treatment approaches, resulting in a poor prognosis. Considerable emphasis and effort must be devoted to colonic squamous cell carcinoma, specifically cases harboring the BRAFV600E mutation.
期刊介绍:
JMCR is an open access, peer-reviewed online journal that will consider any original case report that expands the field of general medical knowledge. Reports should show one of the following: 1. Unreported or unusual side effects or adverse interactions involving medications 2. Unexpected or unusual presentations of a disease 3. New associations or variations in disease processes 4. Presentations, diagnoses and/or management of new and emerging diseases 5. An unexpected association between diseases or symptoms 6. An unexpected event in the course of observing or treating a patient 7. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect